Parametric Portfolio Associates LLC lifted its holdings in Edwards Lifesciences Corp (NYSE:EW) by 7.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 533,627 shares of the medical research company’s stock after purchasing an additional 36,044 shares during the period. Parametric Portfolio Associates LLC owned 0.25% of Edwards Lifesciences worth $58,331,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of EW. Alps Advisors Inc. boosted its holdings in Edwards Lifesciences by 0.3% during the second quarter. Alps Advisors Inc. now owns 5,102 shares of the medical research company’s stock valued at $603,000 after purchasing an additional 14 shares in the last quarter. Veritable L.P. boosted its holdings in Edwards Lifesciences by 1.2% during the second quarter. Veritable L.P. now owns 6,244 shares of the medical research company’s stock valued at $738,000 after purchasing an additional 71 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its holdings in Edwards Lifesciences by 2.8% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 2,776 shares of the medical research company’s stock valued at $320,000 after purchasing an additional 76 shares in the last quarter. Stephens Inc. AR boosted its holdings in Edwards Lifesciences by 1.2% during the second quarter. Stephens Inc. AR now owns 7,831 shares of the medical research company’s stock valued at $926,000 after purchasing an additional 91 shares in the last quarter. Finally, Johnson Financial Group Inc. boosted its holdings in Edwards Lifesciences by 7.1% during the second quarter. Johnson Financial Group Inc. now owns 1,639 shares of the medical research company’s stock valued at $194,000 after purchasing an additional 109 shares in the last quarter. Institutional investors and hedge funds own 81.00% of the company’s stock.
In other news, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $108.86, for a total value of $576,958.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Larry L. Wood sold 18,960 shares of the business’s stock in a transaction on Monday, October 16th. The shares were sold at an average price of $108.54, for a total transaction of $2,057,918.40. The disclosure for this sale can be found here. Insiders have sold a total of 139,580 shares of company stock valued at $14,887,125 in the last quarter. Corporate insiders own 2.13% of the company’s stock.
Edwards Lifesciences Corp (NYSE EW) opened at $115.45 on Tuesday. The firm has a market cap of $24,175.46, a P/E ratio of 31.65, a P/E/G ratio of 2.04 and a beta of 0.51. Edwards Lifesciences Corp has a 1 year low of $86.55 and a 1 year high of $121.45. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33.
Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The business’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.68 EPS. analysts expect that Edwards Lifesciences Corp will post 3.76 earnings per share for the current fiscal year.
Edwards Lifesciences declared that its Board of Directors has initiated a stock repurchase plan on Thursday, December 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its shares are undervalued.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/12/19/edwards-lifesciences-corp-ew-stake-boosted-by-parametric-portfolio-associates-llc.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.